What drove the intraday move in IOVA stock today?

The intraday rally followed a Q4 revenue beat and positive lifileucel data showing a 50.00% confirmed ORR in early sarcoma patients, plus guidance on a registrational trial. Heavy volume of 54,100,276 shares amplified the price move for IOVA stock.

What is Meyka AI's short-term forecast for IOVA stock?

Meyka AI's forecast model projects a 12‑month target price of $4.60 for IOVA stock, implying about **21.37%** upside from $3.79. Forecasts are model-based projections and not guarantees.

Are Iovance's fundamentals supporting the rally in IOVA stock?

Iovance has improving revenue with full-year product sales of $264.00 million and cash near $303.00 million, but EPS is negative at -1.19 and free cash flow per share is -0.97. Fundamentals show growth with ongoing profitability risk for IOVA stock.

What clinical milestones should IOVA stock investors watch?

Key milestones include the planned Q2 2026 registrational trial start for UPS and DDLPS, FDA engagement outcomes, the Phase 3 TILVANCE-301 melanoma readouts, and real-world Amtagvi adoption metrics. These will drive IOVA stock direction.

US Stocks

IOVA Iovance Biotherapeutics (NASDAQ) up 32.06% after Q4 beat 24 Feb 2026: Lifileucel sarcoma data shifts outlook

ByDanny Kontos February 25, 2026

IOVA stock reached $3.79 intraday on 24 Feb 2026, rising 32.06% after Iovance Biotherapeutics reported a Q4 revenue beat and positive lifileucel results in soft tissue sarcoma. The move follows Q4 product revenue of about $87.00 million and full-year 2025 product sales of $264.00 million, driven by Amtagvi uptake. Intraday volume hit 54,100,276 shares versus an average of 11,142,283, signaling heavy buying. We examine the earnings details, clinical catalyst, valuation, technicals, and what the gain means for IOVA stock holders in the United States (NASDAQ) market.